As a result of the current investigation, we found that MA ameliorated IDD development through the PI3K/AKT/NF-κB signaling pathway and the NLRP3 inflammasome-mediated pyroptosis pathway, indicating that MA was a viable medication for IDD treatment. This evidence concerns the gene NLRP3 and intervertebral disk degenerative disorder.